These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 30869490)

  • 1. Childhood obesity: Pharmacokinetics considerations for drugs used in the Intensive Care Unit.
    Donoso F A; Ulloa V D; Contreras E D; Arriagada S D
    Arch Argent Pediatr; 2019 Apr; 117(2):e121-e130. PubMed ID: 30869490
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pediatric Obesity: Pharmacokinetics and Implications for Drug Dosing.
    Kendrick JG; Carr RR; Ensom MH
    Clin Ther; 2015 Sep; 37(9):1897-923. PubMed ID: 26361823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Drug absorption, distribution, metabolism and excretion considerations in critically ill adults.
    Roberts DJ; Hall RI
    Expert Opin Drug Metab Toxicol; 2013 Sep; 9(9):1067-84. PubMed ID: 23682923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Drug dosage in obese children].
    Gade C; Christensen HR; Holst H
    Ugeskr Laeger; 2015 Oct; 177(44):V05150446. PubMed ID: 26509544
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic drug-drug interactions in the intensive care unit - single-centre experience and literature review.
    Łój P; Olender A; Ślęzak W; Krzych ŁJ
    Anaesthesiol Intensive Ther; 2017; 49(4):259-267. PubMed ID: 29027654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Altered pharmacology in the Intensive Care Unit patient.
    Zagli G; Tarantini F; Bonizzoli M; Di Filippo A; Peris A; De Gaudio AR; Geppetti P
    Fundam Clin Pharmacol; 2008 Oct; 22(5):493-501. PubMed ID: 18684127
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development of recommendations for dosing of commonly prescribed medications in critically ill obese children.
    Ross EL; Heizer J; Mixon MA; Jorgensen J; Valdez CA; Czaja AS; Reiter PD
    Am J Health Syst Pharm; 2015 Apr; 72(7):542-56. PubMed ID: 25788508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. How to measure pharmacokinetics in critically ill patients?
    Liu X; Kruger PS; Roberts MS
    Curr Pharm Biotechnol; 2011 Dec; 12(12):2037-43. PubMed ID: 21554213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Pharmacology Studies in Critically Ill Children.
    Thakkar N; Salerno S; Hornik CP; Gonzalez D
    Pharm Res; 2017 Jan; 34(1):7-24. PubMed ID: 27585904
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Editorial: Recent Advances in Developmental Drug Disposition.
    Collier AC
    Drug Metab Lett; 2015; 9(2):64. PubMed ID: 26517862
    [No Abstract]   [Full Text] [Related]  

  • 11. [Personalised pharmacotherapy in intensive care unit patients].
    Bellmann R
    Med Klin Intensivmed Notfmed; 2017 May; 112(4):289-294. PubMed ID: 28466289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obesity and Pediatric Drug Development.
    Vaughns JD; Conklin LS; Long Y; Zheng P; Faruque F; Green DJ; van den Anker JN; Burckart GJ
    J Clin Pharmacol; 2018 May; 58(5):650-661. PubMed ID: 29350758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Effects of Obesity on Drug Metabolism in Children.
    Oeser SG; Rougee LR; Collier AC
    Drug Metab Lett; 2015; 9(2):88-98. PubMed ID: 26411468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacotherapy during pediatric extracorporeal membrane oxygenation: a review.
    Himebauch AS; Kilbaugh TJ; Zuppa AF
    Expert Opin Drug Metab Toxicol; 2016 Oct; 12(10):1133-42. PubMed ID: 27322360
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetic considerations in critically ill patients].
    Escobar L; Gai MN; Regueira T; Andresen M
    Rev Med Chil; 2012 Jun; 140(6):780-8. PubMed ID: 23282618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The obese child in the Intensive Care Unit. Update.
    Donoso Fuentes A; Córdova L P; Hevia J P; Arriagada S D
    Arch Argent Pediatr; 2016 Jun; 114(3):258-166. PubMed ID: 27164340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetic considerations in the obese.
    Leykin Y; Miotto L; Pellis T
    Best Pract Res Clin Anaesthesiol; 2011 Mar; 25(1):27-36. PubMed ID: 21516911
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Population pharmacokinetics/pharmacodynamics of micafungin against Candida species in obese, critically ill, and morbidly obese critically ill patients.
    Maseda E; Grau S; Luque S; Castillo-Mafla MP; Suárez-de-la-Rica A; Montero-Feijoo A; Salgado P; Gimenez MJ; García-Bernedo CA; Gilsanz F; Roberts JA
    Crit Care; 2018 Apr; 22(1):94. PubMed ID: 29655372
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of obesity on the pharmacokinetics of antimicrobials in critically ill patients: A structured review.
    Alobaid AS; Hites M; Lipman J; Taccone FS; Roberts JA
    Int J Antimicrob Agents; 2016 Apr; 47(4):259-68. PubMed ID: 26988339
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Obesity in the intensive care unit: risks and complications.
    Selim BJ; Ramar K; Surani S
    Hosp Pract (1995); 2016 Aug; 44(3):146-56. PubMed ID: 27098774
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.